HEAL Act of 2023
- Last Action
- 6/16/2023
Actions
- 2023-06-16Referred to the Subcommittee on Health.
- 2023-06-12Referred to the House Committee on Energy and Commerce.
- 2023-06-12Introduced in House
- 2023-06-12Introduced in House
CRS Summary
As of 2023-06-12 (00)
Halting the Epidemic of Addiction and Loss Act of 2023 or the HEAL Act of 2023
This bill requires the Department of Health and Human Services (HHS) to ensure that references in its grant programs to opioid overdose reversal agents are inclusive of any such agents that have been approved by the Food and Drug Administration (FDA).
Specifically, HHS must ensure that regulations, guidance, and other documents for grant programs that include references to opioid overdose reversal agents (e.g., naloxone) encompass any opioid overdose reversal agent that has been approved by the FDA. HHS must also update such references with respect to materials that were previously issued for State Opioid Response Grants, Tribal Opioid Response Grants, and Programs of Regional and National Significance for substance use disorder prevention.
Cosponsors (9)
- Paul Tonko (D-NY)
- Brittany Pettersen (D-CO)
- David Trone (D-MD)
- David Joyce (R-OH)
- Derek Kilmer (D-WA)
- Don Bacon (R-NE)
- Ann Kuster (D-NH)
- Michael Lawler (R-NY)
- Chris Pappas (D-NH)
Subjects
- Drug therapy
- Drug trafficking and controlled substances
- Drug, alcohol, tobacco use
- Government information and archives
Sourced from Congress.gov (public domain).
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.